Session: SAT 109-133-GHRH, GH & IGF Biology & Signaling
Bench to Bedside
Poster Board SAT-125
Aim: The aims of this study were 1) to evaluate serum sclerostin levels in patients with acromegaly compared with age- sex and body mass index (BMI)- matched control subjects and 2) to analyze the relationship between sclerostin and PTH, 25- hydroxyvitamin D [25(OH)D], or bone mineral density (BMD) in patients with acromegaly.
Materials and Methods: Thirty-two [n:32, mean age: 48.7±9.4 yrs, M/F:21/11, BMI: 31.8±6.0 kg/m²] patients with acromegaly routinely followed at university hospital were studied. Thirty-four (n:34) age – sex, and BMI (46.2±4.1 yrs, M/F: 28/6, 29.3±4.4 kg/m²) matched subjects were enrolled as the control group.
Results: Serum calcium, 25(OH)D and PTH levels were similar in both groups. No significant difference was observed in femur neck and vertebral T scores. Patients with acromegaly had significantly lower sclerostin levels than the controls (15.4± 8.4 pmol/L vs. 20.6±9.2, p=0.022). Sclerostin levels were similar both in males and females patients with acromegaly (15.1±4.7 vs 15.6±9.9 pmol/L). Sclerostin levels were similiar in patients with active acromegaly (n:8, 11.8±8.5 pmol/L) and controlled acromegaly (n:24, 16.6±8.2 pmol/L). There was no significant correlation between sclerostin and GH, IGF-1 and prolactin levels (r= 0.029; p=0.87, r=-0.065; p=0.72, r=-0.002; p=0.99, respectively).
The prevalence of hypovitaminosis D ( <20 ng/ml) was similiar in acromegalic patients and controls (59.5% and 76.5% respectively, p=0.13). No significant correlation was found between 25(OH)D and sclerostin levels in all participiants. The prevalence of osteoporosis was 21.9% in patients with acromegaly. No significant correlation was found between sclerostin levels and presence of osteoporosis in patients with acromegaly.
Conclusion: Our study is the first report showing a significant lower serum sclerostin levels in acromegaly compared with healthy control subjects. Further studies are required to establish the clinical relevance of sclerostin and GH/IGF1 axes interaction.
Nothing to Disclose: SD, SA, TE
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters